<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686075</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP178</org_study_id>
    <nct_id>NCT00686075</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to &lt;24 Month-old Children and in 2 Month-old Infants</brief_title>
  <official_title>A Phase 1/2a, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to &lt; 24 Month-old Children and in 2 Month-old Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of this study is to describe the safety and tolerability of multiple doses
      of MEDI-534 in children 6 to less than (&lt;) 24 months of age and in infants 2 months of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2a, randomized, double-blind, placebo-controlled, dose-escalation,
      multicenter study to evaluate the safety and tolerability of multiple doses of MEDI-534 at
      10^5 or 10^6 median tissue culture infectious dose (TCID50) in RSV and PIV3 seronegative
      children 6 to &lt;24 months of age and at dosages of 10^4, 10^5 or 10^6 TCID50 in unscreened
      infants 2 months of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Solicited Symptoms After Dose 1</measure>
    <time_frame>Within 28 days after Dose 1</time_frame>
    <description>Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever greater than or equal to (&gt;=) 100.4 degrees Fahrenheit (F), runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Symptoms After Dose 2</measure>
    <time_frame>Within 28 days after Dose 2</time_frame>
    <description>Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever &gt;=100.4 degrees F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Symptoms After Dose 3</measure>
    <time_frame>Within 28 days after Dose 3</time_frame>
    <description>Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever &gt;=100.4 degrees F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 1</measure>
    <time_frame>Within 28 days after Dose 1</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAEs) for Dose 1 are events between administration of Dose 1 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 1 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 2</measure>
    <time_frame>Within 28 days after Dose 2</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-Emergent Adverse Events (TEAEs) for Dose 2 are events between administration of Dose 2 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 2 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 3</measure>
    <time_frame>Within 28 days after Dose 3</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-Emergent Adverse Events (TEAEs) for Dose 3 are events between administration of Dose 3 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 3 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 1</measure>
    <time_frame>Within 28 days after Dose 1</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 1 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 1 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 2</measure>
    <time_frame>Within 28 days after Dose 2</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 2 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 2 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 3</measure>
    <time_frame>Within 28 days after Dose 3</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 3 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 3 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 1</measure>
    <time_frame>Within 28 days after Dose 1</time_frame>
    <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 2</measure>
    <time_frame>Within 28 days after Dose 2</time_frame>
    <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 3</measure>
    <time_frame>Within 28 days after Dose 3</time_frame>
    <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Shed Vaccine-Type Virus</measure>
    <time_frame>7, 12 and 28 days after Dose 1, 2 and 3</time_frame>
    <description>Nasal wash specimens were collected to assess vaccine virus recovery in the upper respiratory tract on 7, 12 and 28 days after each dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Seroresponse to Respiratory Syncytial Virus (RSV) and Human Parainfluenza Virus Type 3 (hPIV3) After Dose 3</measure>
    <time_frame>Day 28 after Dose 3</time_frame>
    <description>Seroresponse was defined as a &gt;=4-fold rise from Baseline in neutralizing antibody titer, regardless of Baseline serostatus. Respiratory Syncytial Virus (RSV) and hPIV3 antibody titers were determined by using microneutralization assay and hemagglutination inhibition assay, respectively. Clopper-pearson exact confidence interval was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic Stability of Recovered Vaccine-Type Virus</measure>
    <time_frame>Within 28 days after any dose</time_frame>
    <description>Nasal wash samples with vaccine-type virus were evaluated for genotypic stability, defined as the presence of the entire RSV-Fusion (RSV F) insert based on the RSV F sequence results. If the insert was absent or truncated, the recovered virus was counted as genotypically unstable. Nasal wash samples were categorized as genotypically stable, genotypically unstable or undetermined genotypic stability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) Through 365 Days After Randomization</measure>
    <time_frame>Day 0 to Day 365</time_frame>
    <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea. MA-LRIs occurring within 28 days post any dose and after 28 days post any dose were summarized separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Significant New Medical Conditions (SNMCs) Through 365 Days After Randomization</measure>
    <time_frame>Day 0 to Day 365</time_frame>
    <description>An SNMC was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. Examples of SNMCs include diabetes, asthma, autoimmune disease (for example, lupus, rheumatoid arthritis), and neurological disease (for example, epilepsy, autism).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through 365 Days After Randomization</measure>
    <time_frame>Day 0 to Day 365</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events after administration of drug which were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) within 365 days after randomization were reported.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">1338</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MEDI-534, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 6 to less than (&lt;) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 6 to &lt;24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-534, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 6 to &lt;24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 6 to &lt;24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-534, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Cohort 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-534, Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Cohort 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI-534, Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Cohort 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-534, Cohort 1</intervention_name>
    <description>Participants aged 6 to less than (&lt;) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
    <arm_group_label>MEDI-534, Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, Cohort 1</intervention_name>
    <description>Participants aged 6 to &lt;24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
    <arm_group_label>Placebo, Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-534, Cohort 2</intervention_name>
    <description>Participants aged 6 to &lt;24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
    <arm_group_label>MEDI-534, Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, Cohort 2</intervention_name>
    <description>Participants aged 6 to &lt;24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
    <arm_group_label>Placebo, Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-534, Cohort 3</intervention_name>
    <description>Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
    <arm_group_label>MEDI-534, Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, Cohort 3</intervention_name>
    <description>Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
    <arm_group_label>Placebo, Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-534, Cohort 4</intervention_name>
    <description>Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
    <arm_group_label>MEDI-534, Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, Cohort 4</intervention_name>
    <description>Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
    <arm_group_label>Placebo, Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-534, Cohort 5</intervention_name>
    <description>Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
    <arm_group_label>MEDI-534, Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, Cohort 5</intervention_name>
    <description>Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
    <arm_group_label>Placebo, Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female whose age on the day of randomization falls within one of the two age
             groups:

             6 to less than (&lt;) 24 months (more than [&gt;] 6 months of age and not yet reached their
             2nd year birthday), Cohorts 1 and 2 2 months (+/- 4 weeks), Cohorts 3, 4, and 5

          -  Cohorts 1 and 2 only: Subject is seronegative to both Respiratory Syncytial Virus
             (RSV) and human Parainfluenza Virus Type 3 (hPIV3) at Screening

          -  Subject whose gestational age was greater than or equal to (&gt;=) 36 weeks

          -  Subject is in general good health with normal growth (that is, body weight greater
             than (&gt;) third percentile per world health organization [WHO] simplified
             weight-per-age field tables

          -  Subject's legal representative is available by telephone

          -  Written informed consent and Health Insurance Portability and Accountability Act
             (HIPAA) authorization (if applicable) obtained from the subject's legal representative

          -  Subject's legal representative is able to understand and comply with the requirements
             of the protocol as judged by the investigator

          -  Subject is available to complete the follow-up period 1-year after receipt of the
             first dose of study vaccine

          -  Subject's legal representative must be willing and able to bring the subject to the
             study site for evaluation of respiratory illness in accordance with the protocol.

        Exclusion Criteria:

          -  Any fever (&gt;=100.4 degrees Fahrenheit [&gt;=38.0 degrees Celsius], regardless of route)
             or lower respiratory illness within 7 days prior to randomization

          -  Moderate or severe nasal congestion that in the investigator's opinion could interfere
             with intranasal delivery of study vaccine

          -  Acute illness (defined as the presence of moderate or severe signs and symptoms) at
             the time of randomization

          -  Any drug therapy (chronic or other) within 7 days prior to randomization or expected
             receipt through the protocol-specified blood collection 28 days after each study
             vaccine dosing, except that infrequent use of over-the-counter medications for the
             systemic treatment of common childhood symptoms (that is, pain relievers,
             decongestants or cough suppressants) are permitted according to the judgment of the
             investigator

          -  Any current or expected receipt of immunosuppressive agents including steroids (&gt;=2
             milligram per kilogram [mg/kg] per day of prednisone or its equivalent, or &gt;=20
             milligram per day [mg/day] if the subject weighs &gt;10 kilogram [kg], given daily or on
             alternate days for &gt;=14 days); children in this category should not receive study
             vaccine until immunosuppressive agents including corticosteroid therapy have been
             discontinued for &gt;=30 days; the use of topical steroids is permitted according to the
             judgment of the investigator

          -  History of receipt of blood transfusion or expected receipt through the
             protocol-specified blood collection at 28 days after final study dosing

          -  History of receipt of immunoglobulin products or expected receipt through the
             protocol-specified blood collection at 28 days after final study dosing

          -  Receipt of any investigational drug within 60 days prior to randomization or expected
             receipt through 180 days after final study dosing

          -  Receipt of any live virus vaccine (excluding oral polio vaccine and rotavirus vaccine)
             within 28 days prior to randomization or expected receipt within a 28-day window
             around any study vaccine dose

          -  Receipt of any inactivated (that is, non-live) vaccine or oral polio vaccine or
             rotavirus vaccine within 14 days prior to randomization or expected receipt within a
             14-day window around any study vaccine dose

          -  Known or suspected immunodeficiency, including human immunodeficiency virus (HIV)
             infection

          -  Expected to be living in the same home or enrolled in the same classroom at day care
             with infants &lt;6 months within 28 days after each dose

          -  Living in a household with another child who is concurrently enrolled in a study of a
             live viral vaccine (including this study)

          -  Expected contact with a pregnant caregiver within 28 days after each dose

          -  A household contact who is immunocompromised; the subject should also avoid close
             contact with immunocompromised individuals for at least 28 days after any study
             vaccine dose

          -  Expected household contact within 28 days after each dose with a health care provider
             for immunocompromised subjects or who is a day care provider for infants under the age
             of 6 months

          -  History of allergic reaction to any component of the study vaccine

          -  Previous medical history, or evidence, of an intercurrent or chronic illness that, in
             the opinion of the investigator, may compromise the safety of the subject

          -  Known or suspected active or chronic hepatitis infection

          -  History of medical diagnosis of asthma, reactive airway disease, wheezing requiring
             medication, cystic fibrosis, bronchopulmonary dysplasia, chronic pulmonary disease,
             medically confirmed apnea, hospitalization for respiratory illness or mechanical
             ventilation for respiratory illness (excludes elective mechanical ventilation during
             surgery for subjects in Cohorts 1 and 2)

          -  Family member or household contact who is an employee of the research center or
             otherwise involved with the conduct of the study

          -  Any condition that, in the opinion of the investigator, might interfere with study
             vaccine evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elissa Malkin, D.O.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bell Gardens</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Covina</city>
        <state>California</state>
        <zip>91790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bridgeton</city>
        <state>Missouri</state>
        <zip>63044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <zip>18960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poteet</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Passo Fundo-RS</city>
        <state>Rio Grande do Sul</state>
        <zip>99010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05437-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto alegre - RS</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre/RS</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ribeirao Preto - SP</city>
        <zip>14048-990</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01221-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6W3E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kokkola</city>
        <zip>FI-67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuopio</city>
        <zip>FI-70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lahti</city>
        <zip>FI-15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oulu</city>
        <zip>FI-90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pori</city>
        <zip>FI-28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <zip>FI-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Netanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belle Ville Cape Town</city>
        <state>Western Cape</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7824</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almeria</city>
        <state>Andalucia</state>
        <zip>04007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almeria</city>
        <state>Andalucia</state>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almeria</city>
        <state>Andalucia</state>
        <zip>04120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Andalucía</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Catarroja</city>
        <state>Comunidad Valenciana</state>
        <zip>46470</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Eliana, Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46183</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Communidad de</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Sebastian</city>
        <state>Pais Vasco</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Málaga</city>
        <zip>29011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Chile</country>
    <country>France</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <results_first_submitted>September 22, 2014</results_first_submitted>
  <results_first_submitted_qc>September 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2014</results_first_posted>
  <last_update_submitted>September 22, 2014</last_update_submitted>
  <last_update_submitted_qc>September 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus (RSV)</keyword>
  <keyword>Parainfluenza Virus Type 3 (PIV3)</keyword>
  <keyword>MEDI-534</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paramyxoviridae Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 720 participants were randomized in the study. An additional 618 participants were screened but not randomized in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MEDI-534, Cohort 1</title>
          <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Cohort 1</title>
          <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="P3">
          <title>MEDI-534, Cohort 2</title>
          <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="P4">
          <title>Placebo, Cohort 2</title>
          <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="P5">
          <title>MEDI-534, Cohort 3</title>
          <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Cohort 3</title>
          <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="P7">
          <title>MEDI-534, Cohort 4</title>
          <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="P8">
          <title>Placebo, Cohort 4</title>
          <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="P9">
          <title>MEDI-534, Cohort 5</title>
          <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="P10">
          <title>Placebo, Cohort 5</title>
          <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="40"/>
                <participants group_id="P7" count="82"/>
                <participants group_id="P8" count="78"/>
                <participants group_id="P9" count="81"/>
                <participants group_id="P10" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="80"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="40"/>
                <participants group_id="P7" count="82"/>
                <participants group_id="P8" count="77"/>
                <participants group_id="P9" count="80"/>
                <participants group_id="P10" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="37"/>
                <participants group_id="P7" count="82"/>
                <participants group_id="P8" count="76"/>
                <participants group_id="P9" count="75"/>
                <participants group_id="P10" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>MEDI-534, Cohort 1</title>
          <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Cohort 1</title>
          <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="B3">
          <title>MEDI-534, Cohort 2</title>
          <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="B4">
          <title>Placebo, Cohort 2</title>
          <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="B5">
          <title>MEDI-534, Cohort 3</title>
          <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="B6">
          <title>Placebo, Cohort 3</title>
          <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="B7">
          <title>MEDI-534, Cohort 4</title>
          <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="B8">
          <title>Placebo, Cohort 4</title>
          <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="B9">
          <title>MEDI-534, Cohort 5</title>
          <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="B10">
          <title>Placebo, Cohort 5</title>
          <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="80"/>
            <count group_id="B5" value="40"/>
            <count group_id="B6" value="40"/>
            <count group_id="B7" value="82"/>
            <count group_id="B8" value="78"/>
            <count group_id="B9" value="81"/>
            <count group_id="B10" value="79"/>
            <count group_id="B11" value="720"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than (&lt;) 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="82"/>
                    <measurement group_id="B8" value="78"/>
                    <measurement group_id="B9" value="81"/>
                    <measurement group_id="B10" value="79"/>
                    <measurement group_id="B11" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 to &lt;24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="47"/>
                    <measurement group_id="B8" value="41"/>
                    <measurement group_id="B9" value="39"/>
                    <measurement group_id="B10" value="43"/>
                    <measurement group_id="B11" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="37"/>
                    <measurement group_id="B9" value="42"/>
                    <measurement group_id="B10" value="36"/>
                    <measurement group_id="B11" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Symptoms After Dose 1</title>
        <description>Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever greater than or equal to (&gt;=) 100.4 degrees Fahrenheit (F), runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.</description>
        <time_frame>Within 28 days after Dose 1</time_frame>
        <population>Dose 1 safety population included all randomized participants who received study vaccine Dose 1 and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Symptoms After Dose 1</title>
          <description>Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever greater than or equal to (&gt;=) 100.4 degrees Fahrenheit (F), runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.</description>
          <population>Dose 1 safety population included all randomized participants who received study vaccine Dose 1 and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="77"/>
                <count group_id="O9" value="80"/>
                <count group_id="O10" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="27"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="50"/>
                    <measurement group_id="O8" value="48"/>
                    <measurement group_id="O9" value="60"/>
                    <measurement group_id="O10" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 100.4 to 101.4 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 101.5 to 103.1 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 103.2 to 104.9 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: greater than (&gt;) 104.9 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny/stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="36"/>
                    <measurement group_id="O9" value="30"/>
                    <measurement group_id="O10" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="19"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite/decreased urine output</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="44"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="18"/>
                    <measurement group_id="O9" value="41"/>
                    <measurement group_id="O10" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oropharyngeal inflammation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Symptoms After Dose 2</title>
        <description>Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever &gt;=100.4 degrees F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.</description>
        <time_frame>Within 28 days after Dose 2</time_frame>
        <population>Dose 2 safety population included all randomized participants who received study vaccine Dose 2 same as Dose 1 and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Symptoms After Dose 2</title>
          <description>Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever &gt;=100.4 degrees F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.</description>
          <population>Dose 2 safety population included all randomized participants who received study vaccine Dose 2 same as Dose 1 and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="71"/>
                <count group_id="O9" value="73"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="19"/>
                    <measurement group_id="O7" value="38"/>
                    <measurement group_id="O8" value="42"/>
                    <measurement group_id="O9" value="39"/>
                    <measurement group_id="O10" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 100.4 to 101.4 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 101.5 to 103.1 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 103.2 to 104.9 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;104.9 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny/stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="30"/>
                    <measurement group_id="O9" value="25"/>
                    <measurement group_id="O10" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="21"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite/decreased urine output</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="14"/>
                    <measurement group_id="O9" value="22"/>
                    <measurement group_id="O10" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oropharyngeal inflammation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Symptoms After Dose 3</title>
        <description>Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever &gt;=100.4 degrees F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.</description>
        <time_frame>Within 28 days after Dose 3</time_frame>
        <population>Dose 3 safety population included all randomized participants who received study vaccine Dose 3 same as previous doses and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Symptoms After Dose 3</title>
          <description>Solicited symptoms were predefined symptoms or events to be specifically inquired about and assessed daily during the 28-day period after vaccine administration. The solicited symptoms included fever &gt;=100.4 degrees F, runny/stuffy nose, cough, drowsiness, loss of appetite/decreased urine output, irritability/fussiness, oropharyngeal inflammation (laryngitis), and epistaxis.</description>
          <population>Dose 3 safety population included all randomized participants who received study vaccine Dose 3 same as previous doses and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="70"/>
                <count group_id="O9" value="71"/>
                <count group_id="O10" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="36"/>
                    <measurement group_id="O8" value="33"/>
                    <measurement group_id="O9" value="48"/>
                    <measurement group_id="O10" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 100.4 to 101.4 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 101.5 to 103.1 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: 103.2 to 104.9 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;104.9 degrees F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny/stuffy nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="21"/>
                    <measurement group_id="O9" value="32"/>
                    <measurement group_id="O10" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="14"/>
                    <measurement group_id="O8" value="15"/>
                    <measurement group_id="O9" value="25"/>
                    <measurement group_id="O10" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite/decreased urine output</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="10"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability/fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="11"/>
                    <measurement group_id="O9" value="20"/>
                    <measurement group_id="O10" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oropharyngeal inflammation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epistaxis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 1</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAEs) for Dose 1 are events between administration of Dose 1 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 1 were reported.</description>
        <time_frame>Within 28 days after Dose 1</time_frame>
        <population>Dose 1 safety population included all randomized participants who received study vaccine Dose 1 and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 1</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAEs) for Dose 1 are events between administration of Dose 1 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 1 were reported.</description>
          <population>Dose 1 safety population included all randomized participants who received study vaccine Dose 1 and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="77"/>
                <count group_id="O9" value="80"/>
                <count group_id="O10" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="15"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="26"/>
                    <measurement group_id="O9" value="29"/>
                    <measurement group_id="O10" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 2</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-Emergent Adverse Events (TEAEs) for Dose 2 are events between administration of Dose 2 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 2 were reported.</description>
        <time_frame>Within 28 days after Dose 2</time_frame>
        <population>Dose 2 safety population included all randomized participants who received study vaccine Dose 2 same as Dose 1 and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 2</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-Emergent Adverse Events (TEAEs) for Dose 2 are events between administration of Dose 2 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 2 were reported.</description>
          <population>Dose 2 safety population included all randomized participants who received study vaccine Dose 2 same as Dose 1 and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="71"/>
                <count group_id="O9" value="73"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="21"/>
                    <measurement group_id="O8" value="21"/>
                    <measurement group_id="O9" value="25"/>
                    <measurement group_id="O10" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 3</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-Emergent Adverse Events (TEAEs) for Dose 3 are events between administration of Dose 3 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 3 were reported.</description>
        <time_frame>Within 28 days after Dose 3</time_frame>
        <population>Dose 3 safety population included all randomized participants who received study vaccine Dose 3 same as previous doses and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) After Dose 3</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-Emergent Adverse Events (TEAEs) for Dose 3 are events between administration of Dose 3 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TEAEs (spontaneously reported events) after Dose 3 were reported.</description>
          <population>Dose 3 safety population included all randomized participants who received study vaccine Dose 3 same as previous doses and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="70"/>
                <count group_id="O9" value="71"/>
                <count group_id="O10" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="22"/>
                    <measurement group_id="O9" value="29"/>
                    <measurement group_id="O10" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 1</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 1 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 1 were reported.</description>
        <time_frame>Within 28 days after Dose 1</time_frame>
        <population>Dose 1 safety population included all randomized participants who received study vaccine Dose 1 and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 1</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 1 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 1 were reported.</description>
          <population>Dose 1 safety population included all randomized participants who received study vaccine Dose 1 and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="77"/>
                <count group_id="O9" value="80"/>
                <count group_id="O10" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 2</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 2 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 2 were reported.</description>
        <time_frame>Within 28 days after Dose 2</time_frame>
        <population>Dose 2 safety population included all randomized participants who received study vaccine Dose 2 same as Dose 1 and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 2</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 2 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 2 were reported.</description>
          <population>Dose 2 safety population included all randomized participants who received study vaccine Dose 2 same as Dose 1 and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="71"/>
                <count group_id="O9" value="73"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 3</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 3 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 3 were reported.</description>
        <time_frame>Within 28 days after Dose 3</time_frame>
        <population>Dose 3 safety population included all randomized participants who received study vaccine Dose 3 same as previous doses and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) After Dose 3</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events between administration of Dose 3 and up to 28 days after the dose that were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) after Dose 3 were reported.</description>
          <population>Dose 3 safety population included all randomized participants who received study vaccine Dose 3 same as previous doses and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="70"/>
                <count group_id="O9" value="71"/>
                <count group_id="O10" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 1</title>
        <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.</description>
        <time_frame>Within 28 days after Dose 1</time_frame>
        <population>Dose 1 safety population included all randomized participants who received study vaccine Dose 1 and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 1</title>
          <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.</description>
          <population>Dose 1 safety population included all randomized participants who received study vaccine Dose 1 and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="77"/>
                <count group_id="O9" value="80"/>
                <count group_id="O10" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 2</title>
        <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.</description>
        <time_frame>Within 28 days after Dose 2</time_frame>
        <population>Dose 2 safety population included all randomized participants who received study vaccine Dose 2 same as Dose 1 and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 2</title>
          <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.</description>
          <population>Dose 2 safety population included all randomized participants who received study vaccine Dose 2 same as Dose 1 and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="65"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="71"/>
                <count group_id="O9" value="73"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 3</title>
        <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.</description>
        <time_frame>Within 28 days after Dose 3</time_frame>
        <population>Dose 3 safety population included all randomized participants who received study vaccine Dose 3 same as previous doses and had safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) After Dose 3</title>
          <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea.</description>
          <population>Dose 3 safety population included all randomized participants who received study vaccine Dose 3 same as previous doses and had safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="76"/>
                <count group_id="O8" value="70"/>
                <count group_id="O9" value="71"/>
                <count group_id="O10" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Shed Vaccine-Type Virus</title>
        <description>Nasal wash specimens were collected to assess vaccine virus recovery in the upper respiratory tract on 7, 12 and 28 days after each dosing.</description>
        <time_frame>7, 12 and 28 days after Dose 1, 2 and 3</time_frame>
        <population>Shedding population included all randomized participants who received study vaccine and had valid shedding data after the specified dose. ‘N’ (number of participants analyzed) = participants who were evaluable for this measure; and 'n' = participants who were evaluable for this measure at given time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Shed Vaccine-Type Virus</title>
          <description>Nasal wash specimens were collected to assess vaccine virus recovery in the upper respiratory tract on 7, 12 and 28 days after each dosing.</description>
          <population>Shedding population included all randomized participants who received study vaccine and had valid shedding data after the specified dose. ‘N’ (number of participants analyzed) = participants who were evaluable for this measure; and 'n' = participants who were evaluable for this measure at given time points for each group, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="78"/>
                <count group_id="O4" value="79"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="77"/>
                <count group_id="O9" value="78"/>
                <count group_id="O10" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1: Day 7 (n=76,76,78,79,40,39,82,77,78,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="50"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="52"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1: Day 12 (n=75,78,78,78,40,40,81,76,78,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="22"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1: Day 28 (n=76,77,77,78,39,40,82,76,77,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2: Day 7 (n=62,65,65,63,25,26,75,70,72,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="13"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2: Day 12 (n=63,65,65,64,25,25,76,71,72,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2: Day 28 (n=63,65,65,65,25,26,76,71,73,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 3: Day 7 (n=58,59,62,59,28,30,75,70,69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="18"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 3: Day 12 (n=59,60,61,61,28,29,76,70,70,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 3: Day 28 (n=60,60,63,61,28,30,76,70,71,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Seroresponse to Respiratory Syncytial Virus (RSV) and Human Parainfluenza Virus Type 3 (hPIV3) After Dose 3</title>
        <description>Seroresponse was defined as a &gt;=4-fold rise from Baseline in neutralizing antibody titer, regardless of Baseline serostatus. Respiratory Syncytial Virus (RSV) and hPIV3 antibody titers were determined by using microneutralization assay and hemagglutination inhibition assay, respectively. Clopper-pearson exact confidence interval was reported.</description>
        <time_frame>Day 28 after Dose 3</time_frame>
        <population>Immunogenicity population included all randomized participants who received study vaccine for the specified dose and had valid immunogenicity data. 'N' (number of participants analyzed) = participants evaluable for this measure; and ‘n’ = participants evaluable for specified virus type, for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Seroresponse to Respiratory Syncytial Virus (RSV) and Human Parainfluenza Virus Type 3 (hPIV3) After Dose 3</title>
          <description>Seroresponse was defined as a &gt;=4-fold rise from Baseline in neutralizing antibody titer, regardless of Baseline serostatus. Respiratory Syncytial Virus (RSV) and hPIV3 antibody titers were determined by using microneutralization assay and hemagglutination inhibition assay, respectively. Clopper-pearson exact confidence interval was reported.</description>
          <population>Immunogenicity population included all randomized participants who received study vaccine for the specified dose and had valid immunogenicity data. 'N' (number of participants analyzed) = participants evaluable for this measure; and ‘n’ = participants evaluable for specified virus type, for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="68"/>
                <count group_id="O8" value="59"/>
                <count group_id="O9" value="63"/>
                <count group_id="O10" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RSV (n=44, 51, 50, 51, 19, 19, 68, 59, 63, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" lower_limit="16.8" upper_limit="45.2"/>
                    <measurement group_id="O2" value="17.6" lower_limit="8.4" upper_limit="30.9"/>
                    <measurement group_id="O3" value="36.0" lower_limit="22.9" upper_limit="50.8"/>
                    <measurement group_id="O4" value="25.5" lower_limit="14.3" upper_limit="39.6"/>
                    <measurement group_id="O5" value="15.8" lower_limit="3.4" upper_limit="39.6"/>
                    <measurement group_id="O6" value="5.3" lower_limit="0.1" upper_limit="26.0"/>
                    <measurement group_id="O7" value="7.4" lower_limit="2.4" upper_limit="16.3"/>
                    <measurement group_id="O8" value="3.4" lower_limit="0.4" upper_limit="11.7"/>
                    <measurement group_id="O9" value="0.0" lower_limit="0.0" upper_limit="5.7"/>
                    <measurement group_id="O10" value="0.0" lower_limit="0.0" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hPIV3 (n=55, 53, 51, 53, 20, 22, 65, 59, 57, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" lower_limit="53.3" upper_limit="79.3"/>
                    <measurement group_id="O2" value="7.5" lower_limit="2.1" upper_limit="18.2"/>
                    <measurement group_id="O3" value="86.3" lower_limit="73.7" upper_limit="94.3"/>
                    <measurement group_id="O4" value="11.3" lower_limit="4.3" upper_limit="23.0"/>
                    <measurement group_id="O5" value="35.0" lower_limit="15.4" upper_limit="59.2"/>
                    <measurement group_id="O6" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O7" value="16.9" lower_limit="8.8" upper_limit="28.3"/>
                    <measurement group_id="O8" value="5.1" lower_limit="1.1" upper_limit="14.1"/>
                    <measurement group_id="O9" value="19.3" lower_limit="10.0" upper_limit="31.9"/>
                    <measurement group_id="O10" value="5.8" lower_limit="1.2" upper_limit="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Genotypic Stability of Recovered Vaccine-Type Virus</title>
        <description>Nasal wash samples with vaccine-type virus were evaluated for genotypic stability, defined as the presence of the entire RSV-Fusion (RSV F) insert based on the RSV F sequence results. If the insert was absent or truncated, the recovered virus was counted as genotypically unstable. Nasal wash samples were categorized as genotypically stable, genotypically unstable or undetermined genotypic stability.</description>
        <time_frame>Within 28 days after any dose</time_frame>
        <population>Shedding population included all randomized participants who received study vaccine and had valid shedding data. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Genotypic Stability of Recovered Vaccine-Type Virus</title>
          <description>Nasal wash samples with vaccine-type virus were evaluated for genotypic stability, defined as the presence of the entire RSV-Fusion (RSV F) insert based on the RSV F sequence results. If the insert was absent or truncated, the recovered virus was counted as genotypically unstable. Nasal wash samples were categorized as genotypically stable, genotypically unstable or undetermined genotypic stability.</description>
          <population>Shedding population included all randomized participants who received study vaccine and had valid shedding data. ‘N’ (number of participants analyzed) signifies those participants who were evaluable for this measure.</population>
          <units>nasal wash samples</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="67"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="60"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>nasal wash samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="59"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="141"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="117"/>
                <count group_id="O10" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Genotypically stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O5" value="54"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="135"/>
                    <measurement group_id="O9" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotypically unstable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undetermined genotypic stability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) Through 365 Days After Randomization</title>
        <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea. MA-LRIs occurring within 28 days post any dose and after 28 days post any dose were summarized separately.</description>
        <time_frame>Day 0 to Day 365</time_frame>
        <population>Safety population included all randomized participants who received study vaccine and had any safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Medically-Attended Lower Respiratory Illnesses (MA-LRIs) Through 365 Days After Randomization</title>
          <description>An MA-LRI was a healthcare provider-confirmed diagnosis of one or more of the following events: wheezing, pneumonia, croup (laryngotracheobronchitis), rhonchi (not cleared with cough or suctioning), rales (not cleared with cough or suctioning), bronchitis, bronchiolitis, and apnea. MA-LRIs occurring within 28 days post any dose and after 28 days post any dose were summarized separately.</description>
          <population>Safety population included all randomized participants who received study vaccine and had any safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="77"/>
                <count group_id="O9" value="80"/>
                <count group_id="O10" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 28 days post any dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="10"/>
                    <measurement group_id="O10" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 28 days post any dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="20"/>
                    <measurement group_id="O9" value="23"/>
                    <measurement group_id="O10" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Significant New Medical Conditions (SNMCs) Through 365 Days After Randomization</title>
        <description>An SNMC was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. Examples of SNMCs include diabetes, asthma, autoimmune disease (for example, lupus, rheumatoid arthritis), and neurological disease (for example, epilepsy, autism).</description>
        <time_frame>Day 0 to Day 365</time_frame>
        <population>Safety population included all randomized participants who received study vaccine and had any safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Significant New Medical Conditions (SNMCs) Through 365 Days After Randomization</title>
          <description>An SNMC was a newly diagnosed medical condition that was of a chronic, ongoing nature and was assessed by the investigator as medically significant. Examples of SNMCs include diabetes, asthma, autoimmune disease (for example, lupus, rheumatoid arthritis), and neurological disease (for example, epilepsy, autism).</description>
          <population>Safety population included all randomized participants who received study vaccine and had any safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="77"/>
                <count group_id="O9" value="80"/>
                <count group_id="O10" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through 365 Days After Randomization</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events after administration of drug which were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) within 365 days after randomization were reported.</description>
        <time_frame>Day 0 to Day 365</time_frame>
        <population>Safety population included all randomized participants who received study vaccine and had any safety follow-up data.</population>
        <group_list>
          <group group_id="O1">
            <title>MEDI-534, Cohort 1</title>
            <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Cohort 1</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O3">
            <title>MEDI-534, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Cohort 2</title>
            <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O5">
            <title>MEDI-534, Cohort 3</title>
            <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Cohort 3</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O7">
            <title>MEDI-534, Cohort 4</title>
            <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Cohort 4</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O9">
            <title>MEDI-534, Cohort 5</title>
            <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
          <group group_id="O10">
            <title>Placebo, Cohort 5</title>
            <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) Through 365 Days After Randomization</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-Emergent Serious Adverse Events (TESAEs) are serious events after administration of drug which were absent before treatment or that worsened relative to pretreatment state. Number of participants with unsolicited TESAEs (spontaneously reported events) within 365 days after randomization were reported.</description>
          <population>Safety population included all randomized participants who received study vaccine and had any safety follow-up data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="80"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="82"/>
                <count group_id="O8" value="77"/>
                <count group_id="O9" value="80"/>
                <count group_id="O10" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 to Day 365</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MEDI-534, Cohort 1</title>
          <description>Participants aged 6 to less than (&lt;) 24 months received MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="E2">
          <title>Placebo, Cohort 1</title>
          <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="E3">
          <title>MEDI-534, Cohort 2</title>
          <description>Participants aged 6 to &lt;24 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="E4">
          <title>Placebo, Cohort 2</title>
          <description>Participants aged 6 to &lt;24 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="E5">
          <title>MEDI-534, Cohort 3</title>
          <description>Participants aged 2 months received MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="E6">
          <title>Placebo, Cohort 3</title>
          <description>Participants aged 2 months received placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="E7">
          <title>MEDI-534, Cohort 4</title>
          <description>Participants aged 2 months received MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="E8">
          <title>Placebo, Cohort 4</title>
          <description>Participants aged 2 months received placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="E9">
          <title>MEDI-534, Cohort 5</title>
          <description>Participants aged 2 months received MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
        <group group_id="E10">
          <title>Placebo, Cohort 5</title>
          <description>Participants aged 2 months received placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Measles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="78"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="80"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="40"/>
                <counts group_id="E7" subjects_affected="45" subjects_at_risk="82"/>
                <counts group_id="E8" subjects_affected="42" subjects_at_risk="77"/>
                <counts group_id="E9" subjects_affected="50" subjects_at_risk="80"/>
                <counts group_id="E10" subjects_affected="44" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tympanic membrane hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E2" events="26" subjects_affected="16" subjects_at_risk="79"/>
                <counts group_id="E3" events="23" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E4" events="24" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E9" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E10" events="7" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Infantile colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="40" subjects_affected="21" subjects_at_risk="78"/>
                <counts group_id="E2" events="53" subjects_affected="20" subjects_at_risk="79"/>
                <counts group_id="E3" events="44" subjects_affected="22" subjects_at_risk="80"/>
                <counts group_id="E4" events="39" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tongue geographic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="80"/>
                <counts group_id="E4" events="17" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E9" events="9" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vomiting projectile</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Multiple allergies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Adenoviral conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="7" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Candida nappy rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Coxsackie viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E9" events="8" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E10" events="13" subjects_affected="7" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Omphalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E2" events="31" subjects_affected="26" subjects_at_risk="79"/>
                <counts group_id="E3" events="29" subjects_affected="22" subjects_at_risk="80"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="80"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E7" events="18" subjects_affected="15" subjects_at_risk="82"/>
                <counts group_id="E8" events="13" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E9" events="18" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E10" events="17" subjects_affected="14" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Gingival injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Occult blood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="7" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dandruff</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="79"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E8" events="8" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E10" events="4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Seborrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Urticaria papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome. The PIs also agree for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Filip Dubovsky, Vice President, Clinical Development</name_or_title>
      <organization>MedImmune, LLC.</organization>
      <phone>301-398-0000</phone>
      <email>dubovskyf@medimmune.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

